627 related articles for article (PubMed ID: 17525889)
21. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
22. Historical perspective on the treatment of essential thrombocythemia and polycythemia vera.
Gilbert HS
Semin Hematol; 1999 Jan; 36(1 Suppl 2):19-22. PubMed ID: 9930553
[TBL] [Abstract][Full Text] [Related]
23. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
[TBL] [Abstract][Full Text] [Related]
24. Evidence-based management of polycythemia vera.
Barbui T; Finazzi G
Best Pract Res Clin Haematol; 2006; 19(3):483-93. PubMed ID: 16781485
[TBL] [Abstract][Full Text] [Related]
25. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
26. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
27. Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe.
Griesshammer M; Struve S; Harrison CM
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):422-9. PubMed ID: 16810618
[TBL] [Abstract][Full Text] [Related]
28. How to Treat Essential Thrombocythemia and Polycythemia Vera.
Besses C; Alvarez-Larrán A
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S114-23. PubMed ID: 27521307
[TBL] [Abstract][Full Text] [Related]
29. Contemporary approach to essential thrombocythemia and polycythemia vera.
Aruch D; Mascarenhas J
Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
[TBL] [Abstract][Full Text] [Related]
30. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
Elliott MA; Tefferi A
Br J Haematol; 2005 Feb; 128(3):275-90. PubMed ID: 15667529
[TBL] [Abstract][Full Text] [Related]
31. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
32. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.
Marchioli R; Finazzi G; Landolfi R; Kutti J; Gisslinger H; Patrono C; Marilus R; Villegas A; Tognoni G; Barbui T
J Clin Oncol; 2005 Apr; 23(10):2224-32. PubMed ID: 15710945
[TBL] [Abstract][Full Text] [Related]
33. Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.
Elliott MA; Tefferi A
Curr Hematol Rep; 2004 Sep; 3(5):344-51. PubMed ID: 15341701
[TBL] [Abstract][Full Text] [Related]
34. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
[TBL] [Abstract][Full Text] [Related]
35. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.
Gangat N; Wolanskyj AP; Schwager SM; Hanson CA; Tefferi A
Cancer; 2009 Dec; 115(24):5740-5. PubMed ID: 19806641
[TBL] [Abstract][Full Text] [Related]
36. Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia.
Randi ML; Fabris F; Ruzzon E; Pacquola E; Cella G; Girolami A
Haematologica; 2002 Nov; 87(11):1180-4. PubMed ID: 12414348
[TBL] [Abstract][Full Text] [Related]
37. Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia.
Cucuianu A; Stoia M; Farcaş A; Dima D; Zdrenghea M; Paţiu M; Olinic D; Petrov L
Rom J Intern Med; 2006; 44(4):397-406. PubMed ID: 18386616
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic options for essential thrombocythemia and polycythemia vera.
Solberg LA
Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
[TBL] [Abstract][Full Text] [Related]
39. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
40. [Prevention of vascular complications in polycythemia vera and primary thrombocythemia treated with low doses of acetylsalicylic acid].
Fröhli P; Graf C; Rhyner K
Schweiz Med Wochenschr; 1983 Nov; 113(44):1622-7. PubMed ID: 6685916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
